Traders Buy Pfizer (PFE) on Weakness

Investors bought shares of Pfizer Inc. (NYSE:PFE) on weakness during trading hours on Monday. $264.82 million flowed into the stock on the tick-up and $86.08 million flowed out of the stock on the tick-down, for a money net flow of $178.74 million into the stock. Of all companies tracked, Pfizer had the 3rd highest net in-flow for the day. Pfizer traded down ($0.55) for the day and closed at $41.68

Several analysts recently issued reports on PFE shares. Cantor Fitzgerald restated a “buy” rating and set a $53.00 target price on shares of Pfizer in a research report on Wednesday, October 17th. JPMorgan Chase & Co. restated a “buy” rating on shares of Pfizer in a research report on Tuesday, October 30th. Barclays set a $40.00 target price on shares of Pfizer and gave the company a “neutral” rating in a research report on Friday, October 19th. Credit Suisse Group set a $40.00 target price on shares of Pfizer and gave the company a “hold” rating in a research report on Sunday, October 14th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a report on Tuesday, October 23rd. They set a “market perform” rating on the stock. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and seven have given a buy rating to the stock. Pfizer has a consensus rating of “Hold” and an average price target of $44.68.

The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The firm has a market capitalization of $251.39 billion, a P/E ratio of 13.89, a price-to-earnings-growth ratio of 2.42 and a beta of 0.77.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The firm had revenue of $13.98 billion for the quarter, compared to the consensus estimate of $13.92 billion. During the same quarter in the previous year, the firm earned $0.62 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 1st will be issued a $0.36 dividend. This represents a $1.44 annualized dividend and a dividend yield of 3.45%. The ex-dividend date is Thursday, January 31st. This is an increase from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s payout ratio is 48.00%.

Pfizer declared that its board has approved a stock repurchase program on Friday, December 14th that authorizes the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 3.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

In related news, EVP Douglas M. Lankler sold 5,000 shares of the business’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the sale, the executive vice president now owns 83,592 shares in the company, valued at $3,573,558. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 38,800 shares of the business’s stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the completion of the sale, the executive vice president now owns 83,592 shares in the company, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Advocacy Wealth Management Services LLC increased its position in Pfizer by 48.2% in the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 258 shares during the last quarter. Winch Advisory Services LLC increased its position in Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 336 shares during the last quarter. 1 North Wealth Services LLC bought a new position in Pfizer during the fourth quarter valued at $40,000. Ruggie Capital Group bought a new position in Pfizer during the fourth quarter valued at $44,000. Finally, Contravisory Investment Management Inc. increased its position in Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 745 shares during the last quarter. Institutional investors own 70.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2019/02/11/traders-buy-pfizer-pfe-on-weakness.html.

About Pfizer (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Debt-To-Equity Ratio

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply